Vimarsana
Biggest News Aggregation in the World

Hematologic Adverse Events News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Hematologic Adverse Events. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Hematologic Adverse Events Today - Breaking & Trending Today

New Publication Highlights Real World Impact of Trilaciclib on Myelosuppressive Events in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) - Vimarsana News

New Publication Highlights Real World Impact of Trilaciclib on Myelosuppressive Events in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Published: July 31, 2023

- Results Confirm that Trilaciclib Reduces Single and Multilineage Grade ≥3 Myelosuppressive Hematologic Adverse Events Including Neutropenia, Anemia, and Thrombocytopenia - - Analyses Showed...

Source: marketscreener.com
Related Topics:
United StatesJerome GoldschmidtUs Oncology NetworkExchange CommissionGlobenewswire IncInvestor Relations Corporate CommunicationsBlue Ridge Cancer CenterTherapeutics IncResearch Triangle ParkTrilaciclib Reduces SingleMultilineage GradeHematologic Adverse EventsIncluding NeutropeniaMedical OncologistRidge Cancer CenterWorld OutcomesTrilaciclib Among PatientsTriangle ParkPrivate Securities Litigation Reform ActInvestor Relations
Optimizing Use of RET Inhibitors in Patients With RR DTC - Vimarsana News

Optimizing Use of RET Inhibitors in Patients With RR DTC

Published: May 29, 2023

Shared insight on the optimal use of RET inhibitor therapy in select patients with RET-rearranged radioiodine-refractory differentiated thyroid cancer.

Source: onclive.com
Related Topics:
Treatment ApproachesSequencing StrategiesDifferentiated Thyroid CancerPatients WithThyroid CancerDtc CancerRet FusionsRet ExpressionRet InhibitorAdverse EventsDrug Adverse EventsHematologic AesHematologic Adverse Events